The firm last week announced it received funding that will allow it to complete development of the test, called Myelo-Scan, by the end of 2026.

Within three years, the project anticipates at least one test for the early-stage detection of Alzheimer's disease could be ready for commercialization.

NEW YORK – German digital pathology company Mindpeak announced Monday that it has raised $15.3 million in a Series A financing round.

The Cambridge, UK-based firm said that the project will help it to develop its breath-based tests and support the development of tools for breath-based testing.

Less than one quarter of pathology labs have adopted whole-slide imaging so far, but pathologists and companies in the space ...

The University of Maryland spinout said it plans to launch a point-of-care urinary tract infection test by 2025, followed by three more tests by 2028.

NEW YORK – What were the articles that gained the most interest from 360Dx readers last week? Here are the top five: ...

The deal comes on the heels of a similar arrangement Nanostics struck with Protean BioDiagnostics for the US market.

NEW YORK – The Alzheimer's Drug Discovery Foundation on Wednesday announced that it has invested $7.0 million in Alzheimer's disease diagnostic company C2N Diagnostics. Already have a 360Dx or ...

The change applies to qualitative and quantitative hepatitis B virus antigen, antibody, and nucleic acid assays that are used to detect acute and chronic infections.

Trinity plans to bring to market in 2025 Metabolomics Diagnostics' PrePsia test that can be used to determine preeclampsia risk in the 12th week of pregnancy.

The tool uses two blood-based biomarkers and up to five clinical features to generate a risk score for prostate cancer aggressiveness.